✦ LIBER ✦

Management of patients with HER2-positive metastatic breast cancer: Is there an optimal sequence of HER2-directed approaches?

✍ Scribed by Zelnak, Amelia B.; Wisinski, Kari B.

Book ID: 126140595
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 299 KB
Volume: 121
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.28815

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Optimizing the management of HER2-negati

Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda)

✍ Robert Leonard; David Miles; Peter Reichardt; Chris Twelves 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 159 KB

Optimal Duration of Cardiac Monitoring i

Optimal Duration of Cardiac Monitoring in Metastatic HER2-positive Breast Cancer Patients Receiving Trastuzumab

✍ Chiu, K.; Dubey, S.; Bull, D. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Prognostic value of HER2-positive circul

Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer

✍ Naoki Hayashi; Seigo Nakamura; Yasuharu Tokuda; Yuji Shimoda; Hiroshi Yagata; At 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 260 KB

Emerging treatment options for the manag

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer

✍ A. Jo Chien, Hope S. Rugo 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 232 KB

The role of trastuzumab in the managemen

The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review

✍ Yutaka Tokuda; Yasuhiro Suzuki; Yuki Saito; Shinobu Umemura 📂 Article 📅 2009 🏛 Springer Japan 🌐 English ⚖ 234 KB

Phase I Study of Trastuzumab-DM1, an HER

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

✍ Krop, I. E.; Beeram, M.; Modi, S.; Jones, S. F.; Holden, S. N.; Yu, W.; Girish, 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 153 KB